Clinical trial NCT07017114: Pentoxifylline PKB171 Gel in Healthy Females Volunteers
Official title: Phase I, Dose-Escalation Clinical Trial to Evaluate the Safety and Tolerability of Pentoxifylline PKB171 Gel in Single-Dose Intravaginal Administration, Followed by an Extension Study With Multiple-Dose Administration in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Safety
Pharmacokinetics
Maximum Tolerated Dose
Keywords: Pharmacokinetics
Maximum tolerated dose (MTD)
Local tolerability
pentoxifyline PKB171 Gel
Lead sponsor: Prokrea BCN, S.L.
Sponsor class: INDUSTRY
Collaborators: name: TFS Trial Form Support
First posted: 2025-06-12
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Dose-Escalation:

A single dose of PKB171 vaginal gel (5 g) was intravaginally administered to healthy volunteers. Three strengths of PKB171 gel were tested: 2% (100 mg), 3% (150 mg) and 4% (200 mg).

Three cohorts of 8 healthy female volunteers participated. For each dose level, subjects were randomly allocated to receive either the study drug or the placebo (3:1) between day 7 and 21 of their menstrual cycle.

Safety and tolerability of each strength level and dose-escalation decisions. Full PK profile of PKB171 at each dose, blood samples (10 ml) were collected at baseline (pre-treatment), 10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 h, 2 h, 4 h, 8 h and 24 hours post-adm were made based on the occurrence of drug-related adverse events (AEs).

Multiple-dose extension substudy:

The extension substudy was planned in order to assess the tolerability and PK of PKB171 after multiple-dose administration (two consecutive days) using the MTD in healthy female volunteers.
Primary purpose: OTHER

Brief summary: A Phase I, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Clinical Trial to evaluate the Safety and Tolerability of Pentoxifylline PKB171 Gel in Single-Dose Intravaginal Administration, followed by an Extension Study with Multiple-Dose Administration in Healthy Volunteers. The primary ojective was to determine the maximum tolerated dose (MTD) in terms of local tolerability of PKB171 after single-dose intravaginal administration in healthy female volunteers; the secondary objectives evaluated the safety and tolerability of PKB171 after single-dose intravaginal administration and the pharmacokinetic (PK) profile of PKB171 after single-dose intravaginal administration.

The extension substudy evaluated the safety and tolerability of PKB171 after multiple-dose intravaginal administration at the MTD in healthy volunteers.

Detailed description: Phase I, randomised, double-blind, placebo-controlled, dose-escalation study to determine the MTD of PKB171 after single-dose intravaginal administration, followed by a double-blind extension study with multiple-dose vaginal administration (two consecutive days) of PKB171at the MTD in healthy volunteers.

Part A. Dose-Escalation:

A single dose of PKB171 vaginal gel (5 g) was intravaginally administered to healthy volunteers. Three strengths of PKB171 gel were tested: 2% (100 mg pentoxifyline), 3% (150 mg pentoxifyline) and 4% (200 mg pentoxifyline).

Three cohorts of 8 healthy female volunteers participated. Intrapatient dose escalation was not permitted. For each dose level, subjects were randomly allocated to receive either the study drug or the placebo (3:1) between day 7 and 21 of their menstrual cycle. In the first cohort (cohort A), a first volunteer received the study drug; after 24 hours of safety assessment, the rest of the volunteers of that cohort received the study drug (5 volunteers) or placebo (2 volunteers).

Safety and tolerability of each strength level and dose-escalation decisions were made based on the occurrence of drug-related adverse events (AEs). The maximum tolerated dose (MTD) in terms of local tolerability was defined as the highest dose at which no more than 1 of 6 patients experienced a moderate or severe drug-related adverse events following PKB171 gel administration. Dose escalation proceeded until the highest strength of PKB171 vaginal gel (4%) or matching placebo.

To obtain a full PK profile of PKB171 at each dose, blood samples (10 ml) were collected at baseline (pre-treatment), 10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 h, 2 h, 4 h, 8 h and 24 hours post-administration (10 blood draws in total) to analyse the pharmacokinetic parameters (Cmax, Tmax, AUC0-t, T1/2, Vd, Clp) of PKB171 and its metabolite 5-OH-pentoxifylline.

Part B. Multiple-dose extension substudy:

After completing the dose-escalation phase, an extension substudy was planned in order to assess the tolerability and PK of PKB171 after multiple-dose administration (two consecutive days) using the MTD in healthy female volunteers.

A subgroup of 6 patients that have participated in the first part of the study were invited to participate in the randomised, parallel-group, placebo-controlled extension study. Patients were randomly allocated to receive either the study drug or the placebo (2:1) between day 7 and 21 of their menstrual cycle. The MTD of PKB171 gel or matching placebo (5 g) were administered intravaginally in two consecutive days.

Eligibility criteria: Inclusion criteria

Subjects had to fulfil all the following criteria to be eligible for study entry:

1. Understand and agree to the trial procedures and sign an informed consent form.
2. Female volunteers aged between 18 and 45 years.
3. Regular menstrual cycle (regardless of menstrual cycle length)\*

   \*Subjects were asked for the duration of their menstrual cycle and the date of last menstruation in order to identify the stage of their menstrual cycle between days 7 and 21, and depending on their menstrual cycle they were distributed over the three consecutive study periods (and also to have them identified for the extension substudy).
4. Medical records and physical examination showing no organic or psychiatric disorders.
5. Gynaecological examination with visual inspection by the gynaecologist to rule out possible signs/symptoms of inflammation or vaginal infection and/or other gynaecological diseases, such as vulvovaginitis, infectious vulvovaginitis, candidal vulvovaginitis or fungal infection, trichomoniasis, bacterial vaginosis, irritative vulvovaginitis (due to the use of vaginal douching, deodorants, etc.), condylomata or genital warts, bartholinitis, cervicitis, etc. Symptoms: increased vaginal discharge and characteristics' change (colour, smell, texture and appearance) that varied according to the agent causing the infection, redness of the vulvar and vaginal mucosae, warts on the labia and/or anus, painful lump (with abscess), etc.

   In addition, during clinical examination, the gynaecologist asked volunteers about the presence of symptoms (pruritus or itching of the external genitalia and/or vagina, sensation of burning or stinging in the genitalia, urinary tract problems such as frequent urination, burning urination, heavy flow, etc.) to confirm the diagnosis.
6. ECG, vital signs and blood and urine tests performed prior to the trial had to be within normal limits. Minor or one-off variations from the normal limits were allowed at the principal investigator's discretion, insofar as they do not pose a risk to subjects and do not interfere in the evaluation of the drug.
7. Body mass index (BMI=weight/height2) should be between 18.5 and 24.99 kg/m2
8. Women who have not participated in a clinical trial involving drugs in the three months prior to this study.

DIAGNOSIS AND MAIN CRITERIA FOR INCLUSION:

Inclusion criteria

Subjects had to fulfil all the following criteria to be eligible for study entry:

1. Understand and agree to the trial procedures and sign an informed consent form.
2. Female volunteers aged between 18 and 45 years.
3. Regular menstrual cycle (regardless of menstrual cycle length)\*

   \*Subjects were asked for the duration of their menstrual cycle and the date of last menstruation in order to identify the stage of their menstrual cycle between days 7 and 21, and depending on their menstrual cycle they were distributed over the three consecutive study periods (and also to have them identified for the extension substudy).
4. Medical records and physical examination showing no organic or psychiatric disorders.
5. Gynaecological examination with visual inspection by the gynaecologist to rule out possible signs/symptoms of inflammation or vaginal infection and/or other gynaecological diseases, such as vulvovaginitis, infectious vulvovaginitis, candidal vulvovaginitis or fungal infection, trichomoniasis, bacterial vaginosis, irritative vulvovaginitis (due to the use of vaginal douching, deodorants, etc.), condylomata or genital warts, bartholinitis, cervicitis, etc. Symptoms: increased vaginal discharge and characteristics' change (colour, smell, texture and appearance) that varied according to the agent causing the infection, redness of the vulvar and vaginal mucosae, warts on the labia and/or anus, painful lump (with abscess), etc.

   In addition, during clinical examination, the gynaecologist asked volunteers about the presence of symptoms (pruritus or itching of the external genitalia and/or vagina, sensation of burning or stinging in the genitalia, urinary tract problems such as frequent urination, burning urination, heavy flow, etc.) to confirm the diagnosis.
6. ECG, vital signs and blood and urine tests performed prior to the trial had to be within normal limits. Minor or one-off variations from the normal limits were allowed at the principal investigator's discretion, insofar as they do not pose a risk to subjects and do not interfere in the evaluation of the drug.
7. Body mass index (BMI=weight/height2) should be between 18.5 and 24.99 kg/m2
8. Women who have not participated in a clinical trial involving drugs in the three months prior to this study.

Exclusion criteria

Subjects who met any of the following conditions were not selected for this trial:

1. Subjects who were not able to understand the nature of the trial and the procedures that they were asked to follow.
2. History or clinical evidence of gastrointestinal, liver, renal or other types of disorders that led to a change in how the drug was absorbed, distributed, metabolised or excreted, or which suggested drug-induced gastrointestinal upset.
3. History or clinical evidence of psychiatric disorders, alcoholism, abuse of medication or other drugs, or habitual consumption of psychoactive drugs.
4. Any organic disease or major surgery in the 3 months prior to the start of the study.
5. Subjects who had intolerance or serious adverse reactions to the study drugs or any of their ingredients.
6. Regular use of medication in the month prior to the study sessions (including birth control or hormone therapy of any kind), except for vitamins or dietary supplements that, in the opinion of the principal investigator or designated supporting staff, involved no risk to subjects and did not interfere with the study objectives. In this case, subjects had to stop taking them from one week before the experimental sessions and until they had been completed. Treatment with single or limited symptomatic medication in the week prior to the study sessions was not cause for exclusion if it was calculated that it had been completely eliminated by the day of the experimental session.
7. Smoking more than 5 cigarettes a day.
8. Consuming more than 20 g of alcohol a day.
9. Subjects with positive serology for hepatitis B, C or HIV.
10. Women with a positive test for syphilis (RPR: rapid plasma reagin).
11. Pregnant or breast-feeding women.
12. Women who did not commit to using reliable birth control during the study
13. Women who had any contraindication specified in the summary of product characteristics of oral pentoxifylline.

To be eligible, subjects had to agree to the following restrictions regarding diet, sex, drug use and exercise during the study:

1. Did not perform any strenuous physical exercise in the 48 hours prior to the start of each session.
2. Did not take any type of drug from the screening visit to the end of the study.
3. Did not have intercourse relations with penetration in the 24 hours prior to the start of each study visit.

Primary outcomes:
measure: Maximum Tolerated Dose (MTD) of PKB171
timeFrame: 3 weeks
Secondary outcomes:
measure: Adverse events
timeFrame: 3 weeks
measure: Local reactions of PKB171
timeFrame: 3 weeks
measure: Visual Analogue Scale
timeFrame: 3 weeks
measure: Pregnancy
timeFrame: 3 weeks
measure: Peak Plasma Concentration (Cmax)
timeFrame: 3 weeks
measure: Tmax
timeFrame: 3 weeks
measure: Area Under the Curve (AUC0-t)
timeFrame: 3 weeks
measure: Volume of Distribution (Vd)
timeFrame: 3 weeks
measure: Half live (T1/2)
timeFrame: 3 weeks
measure: Blood test for pregnancy
timeFrame: 3 weeks
measure: Plasma Clearance (CLp)
timeFrame: 3 weeks
Other outcomes:
Locations:
Study officials:
affiliation: ProkreaBCN, S.L.
name: José M Palacios, MD
role: STUDY_CHAIR
References: